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DBackground: The number of patients undergoing implantation of a HeartMate II left ventricular assist device
(LVAD; Thoratec Corporation, Pleasanton, Calif) is rising. Ventricular tachyarrhythmia (VA) after placement of
the device is common, especially among patients with preoperative VA. We sought to determine whether intra-
operative cryoablation in select patients reduces the incidence of postoperative VA.
Methods: From January 2009 through September 2010, 50 consecutive patients undergoing implantation of the
HeartMate II LVAD were examined. Fourteen of these patients had recurrent preoperative VA. Of those patients
with recurrent VA, half underwent intraoperative cryoablation (Cryo: n ¼ 7) and half did not (NoCryo: n ¼ 7).
Intraoperatively, patients underwent localized epicardial and endocardial cryoablation via LVAD ventriculot-
omy. Cryothermal lesions were created to connect scar to fixed anatomic borders in the region of clinical
VA. Demographics, risk factors, intraoperative features, and outcomes were analyzed to investigate the feasibil-
ity of cryoablation.
Results: Thirty-day mortality remained low (n¼ 1, 2%) among all LVAD recipients. There were no differences
in risk factors between groups except that preoperative inotropes were less prevalent in Cryo patients (P¼ .09).
Compared with NoCryo, the Cryo group had significantly decreased postoperative resource use and complica-
tions (P<.05). Recurrent postoperative VA did not develop in any of the Cryo patients (P ¼ .02).
Conclusions: Postoperative VA can be minimized by preoperative risk assessment and intraoperative treatment.
Localized cryoablation in select patients offers promising early feasibility when performed during HeartMate II
LVAD implantation. Further prospective analysis is required to investigate this novel approach. (J Thorac Car-
diovasc Surg 2013;145:1207-13)Mechanical left ventricular assist devices (LVADs) have
become accepted as an important therapeutic modality for
patients with end-stage heart failure. Ventricular tachyar-
rhythmias (VAs) are common in patients supported with
LVADs, with reported incidences ranging from 22% to
52%.1-3 As LVAD technology, operative technique, and
postoperative care improve, the duration of LVAD support
is increasing in both bridge-to-transplant and destination
therapy groups. Although tolerance of VAs in the LVAD
population is improved compared with that of
unsupported patients,4 VAs still contribute to mortality, he-
modynamic instability, and prolonged hospitalization in
LVAD recipients.1 A standardized strategy for prevention
and care of VAs is needed to maximize outcomes of patients
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The Journal of Thoracic and CarGiven the high rate of postoperative VAs in LVAD-
supported patients both at our institution and in the litera-
ture, we sought to develop a treatment strategy with the
goal of limiting clinically significant postoperative VAs in
LVAD recipients. A high failure rate was observed with at-
tempts at catheter-based postoperative ablations; therefore,
an intraoperative approach using cryoablation during LVAD
placement was chosen. Patient selection for initial use of
this novel treatment strategy focused on those deemed to
be at highest risk for postoperative VAs. Patients with
more than 1 episode of preoperative VAwere selected to un-
dergo targeted intraoperative epicardial and endocardial
cryoablation at the time of LVAD placement. Initial results
observed in several patients5 prompted further use of this
approach and this study was performed as an early feasibil-
ity analysis of our novel technique.METHODS
Patients
This study was approved by the human investigation committee of the
University of Virginia Health System (HSR 15225). All LVAD operations
at our institution were entered prospectively into The Society of Thoracic
Surgeons (STS) National Database. We retrospectively reviewed all pa-
tients at our institution undergoing placement of a HeartMate II LVAD
(Thoratec Corporation, Pleasanton, Calif) from January 2009 to September
2010. Patient characteristics, demographics, risk factors, operative fea-
tures, and postoperative outcomes were evaluated using a combination ofdiovascular Surgery c Volume 145, Number 5 1207
Abbreviations and Acronyms
Cryo ¼ cryoablation group
EP ¼ electrophysiology
ICU ¼ intensive care unit
LVAD ¼ left ventricular assist device
NoCryo ¼ no cryoablation group
STS ¼ The Society of Thoracic Surgeons
SVR ¼ surgical ventricular reconstruction
VA ¼ ventricular tachyarrhythmia
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DSTS data and data obtained by review of inpatient and outpatient hospital
records. With the exception of VA-related data points, we used known STS
database definitions to describe all preoperative and operative variables as
well as postoperative outcomes. VAwas defined as more than 30 seconds of
documented ventricular tachycardia or ventricular fibrillation as seen on
a rhythm strip, electrocardiographic tracing, or implantable cardiac defi-
brillator readout. ‘‘Recurrent’’ preoperative or postoperative VA was de-
fined as greater than 1 episode of documented VA present at any point
before or after the LVAD operation. Of the 50 consecutive patients, 14
were identified as having recurrent preoperative VAs. These 14 patients,
with multiple episodes of documented VA before LVAD placement, were
separated for subgroup analysis to determine the early feasibility of intra-
operative cryoablation in LVAD recipients with recurrent preoperative VA.
In February 2010, the first patient in our series underwent intraoperative
cryoablation at the time of LVAD implantation. All subsequent patients
with a history of recurrent preoperative VA also underwent intraoperative
cryoablation. Therefore, of the 14 patients with a history of recurrent
VA, the latter 7 underwent intraoperative cryoablation (Cryo); the initial
7 did not (NoCryo). Subgroup analysis comparing these 2 groups of 7 pa-
tients was performed.
Operative Technique
Before LVAD implantation, an effort was made to identify the anatomic
location of arrhythmogenic substrate in those patients selected for intrao-
perative cryoablation. Patients stable enough for transport to the electro-
physiology (EP) laboratory (n ¼ 4) underwent preoperative EP substrate
mapping. In those patients not stable enough for transport (n ¼ 3), electro-
cardiograms capturing ventricular tachycardia were systematically ana-
lyzed by a heart failure cardiologist, electrophysiologist, and cardiac
surgeon to identify the approximate origin of arrhythmogenesis. Standard
HeartMate II LVADs were then placed in all patients. After complete me-
dian sternotomy, the preperitoneal pocket was created to accommodate
the LVAD pump and partial cardiopulmonary bypass was initiated. In pa-
tients undergoing intraoperative ablation, epicardial cryoablation was
then performed using an AtriCure device (AtriCure, Inc, Cincinnati,
Ohio) with a liquid nitrogen–cooled Cryo1 probe (AtriCure; Figure 1).
Each preidentified site of arrhythmogenic substrate was ablated at70C
for 2½minutes. After epicardial ablation, full bypasswas initiated, the aorta
was crossclamped, and cardioplegic solutionwas administered.We opted to
perform the endocardial ablation and LVADplacement on the arrested heart
although these procedures can also be performed on the empty beating
heart. The coring device was used to create a ventriculotomy for placement
of the LVAD inflow cannula and the AtriCure device was again used with
the Cryo1 probe for endocardial ablation via the previously performed ven-
triculotomy (Figure 1). For endocardial ablation in the arrested and nonper-
fused heart, we reduced cryoablation time to 2 minutes, again at70C.
Appropriate loci for cryoablation were identified preoperatively after care-
ful review of EP mapping studies and/or electrocardiograms by the heart
failure cardiologist, electrophysiologist, and cardiac surgeon. To prevent1208 The Journal of Thoracic and Cardiovascular Surdevelopment of subsequent reentry circuits, we took care to ablate the pre-
viously identified arrhythmogenic site in addition to creating a surrounding
ablation tract extending from the arrhythmogenic substrate to fixed ana-
tomic sites such as the mitral valve and/or apical LVAD inflow cannula.
Given the subsequent LVAD ventricular support, maximal ventricular pres-
ervation is not as vital and cryoablation was used liberally, especially when
treating left ventricular lesions. In cases in which multiple or larger areas of
arrhythmogenesis were identified preoperatively, large sections of ventricle
underwent epicardial and endocardial cryoablation. No intraoperative or
routine postoperative EP mapping was performed. After completion of
the endocardial ablation, circumferential stitches were placed at the ventri-
culotomy, the LVAD inflow cannula was seated, and the remainder of the
operation for standard LVAD placement proceeded as per usual.
Statistical Analysis
Our primary outcomes of interest were postoperative VA and recurrent
postoperative VA. Secondary outcomes of interest included mortality and
measures of resource use (ie, length of stay, intensive care unit (ICU)
stay, and various complications). All group comparisons were unpaired. Bi-
variate comparisons with either the Pearson c2 or Fisher exact tests were
used for all categoric variables. Analysis of variance was used for all con-
tinuous variables. Categoric variable comparisons are expressed as per-
centages of each group of origin. Continuous variables are reported as
mean  standard error of the mean. Reported P values are 2-tailed. Data
manipulation and analysis were performed with SPSS software (version
19; SPSS Inc, an IBM Company, Chicago, Ill).
RESULTS
Comparison of Patient Characteristics and
Operative Features
A total of 50 patients underwent HeartMate II LVAD
placement between January 2009 and September 2010. Of
these, 54% (n ¼ 27) had the LVAD placed before the index
intraoperative cryoablation case in February 2010 (Pre-In-
dex) and 46% (n¼ 23) underwent LVAD implantation after
that index case (Post-Index). Comparing the Pre-Index and
Post-Index groups, there were minimal differences in pa-
tient demographics, risk factors, preoperative characteris-
tics, or operative features (Table 1). Both groups were
predominantly male, had a mean age in the 50s, had mainly
nonischemic cardiomyopathy, and had similar preoperative
risk factors. Pre-Index patients had a higher incidence of
preoperative inotrope use (96% vs 70%; P ¼ .01) but no
other significant differences existed between groups. Nota-
bly, both groups had a high rate of documented preoperative
ventricular arrhythmias (Pre-Index, 50.3%; Post-Index,
69.6%; P ¼ .45). As previously mentioned, 14 of 50 total
patients had a history of recurrent preoperative VA (multi-
ple documented episodes of VA before LVAD placement)
and were selected for subgroup analysis. Seven of these pa-
tients were seen before the index case and did not undergo
cryoablation (NoCryo); 7 of these patients were seen after
development of the protocol and thus underwent intraoper-
ative cryoablation in conjunction with their LVAD implan-
tation (Cryo).
Subgroup comparison of the NoCryo and Cryo groups re-
vealed a similarly homogeneous population. No statistically
significant differences were found between groups withgery c May 2013
FIGURE 1. Intraoperative epicardial and endocardial cryoablation.
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Dregard to patient characteristics, risk factors, or operative
features (Table 2). Again, the earlier NoCryo group trended
toward increased preoperative inotrope use (85.7% vs
42.9%; P ¼ .09) but this difference did not reach statistical
significance. As above, both groups were predominantly
male and the majority had nonischemic cardiomyopathy.
Comparison of Outcomes
An analysis of outcomes of all 50 patients undergoing
HeartMate II LVAD implantation during the defined period
reveals no statistically significant difference in outcomes
between those patients undergoing implantation before
the index cryoablation case (Pre-Index) and those patients
undergoing implantation after that case (Post-Index)
(Table 3). Mortality within 30 days was similarly low,
with 1 combined mortality recorded. Mean patient follow-
up was longer in the Pre-Index group (379 vs 148 days;
P<.001) inasmuch as this group underwent surgery at an
earlier date. Postoperative VAs were common in both
groups, with 37% of Pre-Index patients and 26% of Post-
Index patients having at least 1 episode of documented ven-
tricular tachycardia or fibrillation lasting at least 30 seconds
(P ¼ .41). Notably, recurrent postoperative VAs (ie,>1
documented episode) were more common in the Pre-
Index group (18% vs 4%; P ¼ .12) although this trend
did not reach statistical significance. Medical treatment of
both atrial and ventricular arrhythmias followed standard
clinically accepted protocols and was identical between
the Pre-Index and Post-Index groups. Wewere unable to de-
termine the time between surgery and first VA in all patients
but did note that no patient had the first onset of VA outside
a 30-day postoperative period. Complications were com-
mon in both groups with trends toward increased sepsis
(22% vs 4%; P ¼ .07) and prolonged ventilation (74%
vs 48%; P ¼ .06) in the Pre-Index group. Of Pre-Index
patients, 89% had from at least 1 of 14 preselected STS-
defined complications compared with 70% of the Post-
Index group (P ¼ .09). ICU hours, ventilator hours, and
postoperative length of stay were similar in both groups.
A subgroup analysis of outcomes in the 14 patients with
a history of recurrent preoperative VAs reveals a stark differ-
ence in the postoperative course of patients treated withThe Journal of Thoracic and Carintraoperative cryoablation (Cryo group) compared with
those who did not have this procedure (NoCryo group)
(Table 4). No deaths occurred within 30 days in either group.
Two of the Cryo patients had a single episode of docu-
mented of postoperative VAwhereas all 7 of the NoCryo pa-
tients had at least 1 episode of postoperative VA (P ¼ .11).
Of the 2 Cryo patients with a single contained postoperative
VA, 1 had an ischemic etiology of heart failure and the other
nonischemic. In both cases, a single episode of VA occurred
early in the postoperative period and was self-limited. Im-
portantly, none of the Cryo patients had recurrent postoper-
ative VA compared with 4 (57%) of the NoCryo group
(P ¼ .02). Of the 4 NoCryo patients with recurrent postop-
erative VAs, 3 had an identified apical site of the arrhythmo-
genesis as determined by postoperative EP mapping studies.
Although no single complication reached statistical signifi-
cance, patients undergoing intraoperative cryoablation had
fewer complications across the board with 57% having at
least 1 of 14 STS-defined complications compared with
100% of the NoCryo group (P ¼ .05). Looking at the total
number of complications, Cryo patients had a mean of 0.9
complications per patient compared with a mean of 3.0 in
the NoCryo group (P ¼ .05). In addition, Cryo patients
had a dramatically shorter ICU length of stay (165 vs 441
hours; P ¼ .01) and postoperative hospital length of stay
(26 vs 57 days; P ¼ .03).
DISCUSSION
In this study, we have described a novel technique de-
signed to limit postoperative VA in LVAD recipients and
have analyzed the results of our early experience with this
technique. We have shown first that intraoperative epicar-
dial and endocardial cryoablation is a safe technique
when used as described. In addition, when applied to pa-
tients with a history of recurrent preoperative VA, intraoper-
ative cryoablation is effective at limiting the incidence of
recurrent postoperative VA and may contribute to improve-
ments in other patient outcomes. Despite these findings, the
ideal cohort of patients who may benefit from this proce-
dure is unknown. As the incidence of LVAD implantation
and the duration of support increase, effective limitation
of VAs will be essential for the achievement of optimaldiovascular Surgery c Volume 145, Number 5 1209
TABLE 1. Preoperative and operative variables for patients under-










Male 21 (77.8%) 17 (73.9%) .75
Patient age (y) 50.1  13.6 54.8  10.9 .19
Height (cm) 173.4  11.7 174.6  7.2 .67
Weight (kg) 81.1  18.6 85.7  14.1 .34
Risk factors
Peripheral arterial disease 2 (7.4%) 2 (8.7%) .87
Cerebrovascular disease 3 (11.1%) 2 (8.7%) .78
Chronic lung disease 4 (14.8%) 3 (13.0%) .86
Diabetes 8 (29.6%) 5 (21.7%) .53
Family history of CAD 12 (44.4%) 7 (30.4%) .31
Hypertension 10 (37.0%) 13 (56.5%) .17
Renal failure, dialysis 1 (3.7%) 0 (0.0%) .35
Current or recent smoker 2 (7.4%) 2 (8.7%) .87
Previous MI 6 (22.2%) 9 (39.1%) .19
STS cardiogenic shock 20 (74.1%) 16 (69.6%) .72
Ischemic HF 8 (29.6%) 8 (34.8%) .70
Medications
Beta-blockers 13 (48.1%) 16 (69.6%) .13
Coumadin 0 (0.0%) 1 (4.3%) .27
Inotropes 26 (96.3%) 16 (69.6%) .01
Preoperative patient condition
IABP 6 (22.2%) 4 (17.4%) .67
Intubated before VAD 3 (11.1%) 1 (4.3%) .38
Previous AICD 22 (81.5%) 21 (91.3%) .32
Any arrhythmia 22 (81.5%) 20 (87.0%) .60
Atrial fibrillation/flutter 6 (22.2%) 8 (34.8%) .32
Ventricular tachycardia/
fibrillation
16 (59.3%) 16 (69.6%) .45
Ablation procedure 3 (11.1%) 3 (13.0%) .83
Intraoperative
Ablation 0 (0.0%) 7 (30.4%) .002
Crossclamp time (min) 90.8  34.7 83.3  21.1 .40
Perfusion time (min) 147.3  47.3 130.7  34.0 .17
Cryounits 1.0  1.0 0.9  0.8 .64
FFP 6.9  3.1 7.8  6.6 .52
Platelets 1.7  0.8 1.4  0.7 .29
PRBC 2.9  2.4 3.0  4.2 .84
Data are shown as N (%) or mean  standard error of the mean. Boldface indicates
values that are statistically significant. LVAD, Left ventricular assist device; CAD,
coronary artery disease;MI, myocardial infarction; STS, The Society of Thoracic Sur-
geons; HF, heart failure; IABP, intra-aortic balloon pump; VAD, ventricular assist de-
vice; AICD, automatic implantable cardiac defibrillator; FFP, fresh frozen plasma;
PRBC, packed red blood cells.
TABLE 2. Preoperative and operative variables for patients with
a history of recurrent VA undergoing standard LVAD implantations









Male 5 (71.4%) 5 (71.4%) 1.00
Patient age (y) 48.6  18.9 47.9  10.1 .93
Height (cm) 172.2  8.l 174.1  5.5 .63
Weight (kg) 77.5  19.5 87.6  16.1 .33
Risk factors
Peripheral arterial disease 0 (0.0%) 0 (0.0%) 1.00
Cerebrovascular disease 1 (14.3%) 2 (28.6%) .52
Chronic lung disease 1 (14.3%) 0 (0.0%) .30
Diabetes 2 (28.6%) 2 (28.6%) 1.00
Family history of CAD 3 (42.9%) 2 (28.6%) .58
Hypertension 0 (0.0%) 0 (0.0%) 1.00
Renal failure, dialysis 2 (28.6%) 1 (14.3%) .52
Current or recent smoker 0 (0.0%) 1 (14.3%) .30
Previous MI 3 (42.9%) 2 (28.6%) .58
STS cardiogenic shock 4 (57.1%) 3 (42.9%) .59
Ischemic HF 3 (42.9%) 2 (28.6%) .58
Medications
Beta-blockers 5 (71.4%) 6 (85.7%) .52
Coumadin 0 (0.0%) 0 (0.0%) 1.00
Inotropes 6 (85.7%) 3 (42.9%) .09
Preoperative patient condition
IABP 2 (28.6%) 2 (28.6%) 1.00
Intubated before VAD 0 (0.0%) 0 (0.0%) 1.00
Previous AICD 6 (85.7%) 6 (85.7%) 1.00
Any arrhythmia 7 (100.0%) 7 (100.0%) 1.00
Atrial fibrillation/flutter 0 (0.0%) 2 (28.6%) .13
Ventricular tachycardia/
fibrillation
7 (100.0%) 7 (100.0%) 1.00
Ablation procedure 3 (42.9%) 3 (42.9%) 1.00
Intraoperative
Ablation 0 (0.0%) 7 (100.0%) <.001
Crossclamp time (min) 97.4  20.2 83.7  12.9 .18
Perfusion time (min) 163.3  42.5 150.7  30.2 .54
Cryounits 1.6  1.0 1.0  1.0 .30
FFP 7.4  2.4 8.3  4.5 .67
Platelets 1.9  0.7 1.6  0.5 .40
PRBC 4.0  0.8 2.1 4  2.7 .10
Data are shown as N (%) or mean  standard error of the mean. Boldface indicates
values that are statistically significant. VA, Ventricular tachyarrhythmia; LVAD, left
ventricular assist device; NoCryo, no cryoablation group; Cryo, cryoablation group;
CAD, coronary artery disease; MI, myocardial infarction; STS, The Society of Tho-
racic Surgeons; HF, heart failure; IABP, intra-aortic balloon pump; VAD, ventricular
assist device; AICD, automatic implantable cardiac defibrillator; FFP, fresh frozen
plasma; PRBC, packed red blood cells.
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a promising technique, but further refinement and standard-
ization are necessary to achieve optimal results.
Although it is clear that the most important risk factor for
VA in all patients is a reduced ejection fraction,6,7 the direct
relationship between LVADs and VAs is not entirely
understood. Post-LVAD arrhythmias have been attributed
to a host of mechanisms including acute left ventricular1210 The Journal of Thoracic and Cardiovascular Surunloading with pulsatile devices,8 altered ventricular repo-
larization,9 mechanoelectrical feedback from the LVAD
motor,10 alterations in calcium handing gene expression,11
and so called ‘‘suction events.’’12 VAs in all patients are
thought to originate from border-zone areas between car-
diac scar tissue and normal myocardium where fibrosis al-
ters the effective refractory period in the action potentialgery c May 2013
TABLE 3. Postoperative characteristics for patients undergoing










Septicemia 6 (22.2%) 1 (4.3%) .07
Stroke 3 (11.1%) 1 (4.3%) .38
Reoperation for tamponade 6 (22.2%) 5 (21.7%) .97
Other cardiac 3 (11.1%) 1 (4.3%) .38
Other noncardiac 3 (11.1%) 2 (8.7%) .78
Atrial fibrillation 2 (7.4%) 1 (4.3%) .65
Gastrointestinal event 4 (36.4%) 7 (30.4%) .18
Multisystem failure 2 (7.4%) 0 (0.0%) .18
Pneumonia 7 (25.9%) 4 (17.4%) .47
Ventilation prolonged 20 (74.1%) 11 (47.8%) .06
Renal failure 6 (22.2%) 5 (21.7%) .97
Renal dialysis required 2 (7.4%) 2 (8.7%) .87
Embolic stroke 3 (11.1%) 1 (4.3%) .38
Pump pocket infection 0 (0.0%) 1 (4.3%) .27
Any complication 24 (88.9%) 16 (69.6%) .09
Total complications 2.5  2.1 1.8  2.4 .30




10 (37.0%) 6 (26.1%) .41
Recurrent ventricular
tachycardia/fibrillation
5 (18.5%) 1 (4.3%) .12
Ablation shock procedure 3 (11.1%) 0 (0.0%) .10
Hospital stay
Readmission to ICU 7 (25.9%) 3 (13.0%) .26
Reintubated during stay 6 (22.2%) 4 (17.4%) .67
Total ICU time (h) 415.5  337.5 422.6  571.3 .96
Ventilation (h) 143.2  286.2 134.2  287.3 .91
LOS, admission to
discharge
45.4  31.8 43.3  38.6 .61
LOS, admission to surgery 11.9  7.1 9.9  8.5 .38
LOS, surgery to discharge 36.6  31.9 33.4  37.9 .75
Length of follow-up 379.4  136.5 147.7  76.4 <.001
Data are shown as N (%) or mean  standard error of the mean. Boldface indicates
values that are statistically significant. LVAD, Left ventricular assist device; ICU,
intensive care unit; LOS, length of stay.










Septicemia 1 (14.3%) 0 (0.0%) .30
Stroke 1 (14.3%) 0 (0.0%) .30
Reoperation for tamponade 2 (28.6%) 1 (14.3%) .52
Other cardiac 1 (14.3%) 0 (0.0%) .30
Other noncardiac 2 (28.6%) 0 (0.0%) .13
Atrial fibrillation 0 (0.0%) 1 (14.3%) .30
Gastrointestinal event 1 (14.3%) 1 (14.3%) 1.00
Multisystem failure 1 (14.3%) 0 (0.0%) .30
Pneumonia 2 (28.6%) 1 (14.3%) .52
Ventilation prolonged 6 (85.7%) 3 (42.9%) .09
Renal failure 2 (28.6%) 0 (0.0%) .13
Renal dialysis required 1 (14.3%) 0 (0.0%) .30
Embolic stroke 1 (14.3%) 0 (0.0%) .30
Pump pocket infection 0 (0.0%) 0 (0.0%) 1.00
Any complication 7 (100.0%) 4 (57.1%) .05
Total complications 3.0  2.4 0.9  0.9 .05




7 (100.0%) 2 (25.6%) .11
Recurrent ventricular
tachycardia/fibrillation
4 (57.1%) 0 (0.0%) .02
Ablation shock procedure 2 (28.6%) 0 (0.0%) .13
Hospital stay
Readmission to ICU 3 (42.9%) 0 (0.0%) .05
Reintubated during stay 3 (42.9%) 0 (0.0%) .05
Total ICU time (h) 441.5  318.5 165.5  110.0 .01
Ventilation (h) 209.1  388.9 31.3  30.4 .25
LOS, admission to
discharge
71.0  50.3 31.0  16.7 .07
LOS, admission to surgery 14.14  8.8 9.0  12.9 .40
LOS, surgery to discharge 57.0  31.0 26.0  19.0 .03
Length of follow-up 302.9  142.1 144.9  76.6 .02
Data are shown as N (%) or mean  standard error of the mean. Boldface indicates
values that are statistically significant. VA, Ventricular tachyarrhythmia; NoCryo, no
cryoablation group; Cryo, cryoablation group; ICU, intensive care unit; LOS, length
of stay.
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Ventricular stretch is known to be arrhythmogenic,15 so
one may deduce that decompression of the failing ventricle
with LVAD placement should decrease VAs. On the other
hand, LVAD insertion fails to specifically treat areas of ex-
isting ventricular scar, and the LVAD apical cannula neces-
sarily requires creation of new myocardial scar tissue.
Regardless of the relative contribution of these conflicting
factors, multiple previous investigations report an increased
incidence of VAs after LVAD implantation.3,16
Careful analysis of these reports reveals several trends.
First, most patients who have post-LVAD VAs experience
the first episode early in the postoperative period, and 1
episode often predicts future episodes.1,17 In our study, noThe Journal of Thoracic and Carpatient had the first episode of VA outside a 30-day
postoperative period and 38% (6/16) of those with 1
documented VA had subsequent recurrent episodes.
Second, LVAD recipients with preoperative VAs are more
likely to have postoperative VAs.17 Of the 50 patients stud-
ied, 32 had preoperative VA and 41% (n ¼ 13) of these pa-
tients had at least 1 episode of postoperative VA. On the
other hand, of the 18 patients without preoperative VA,
only 17% (n¼ 3) had postoperative VA. Third, the high in-
cidence of VAs after LVAD is cause for concern inasmuch
as mortality is increased among patients with VAs.16 Al-
though the presence of an LVADmitigates the profound he-
modynamic collapse typically seen in unsupported patients,
a decrease in LVAD flow output has been demonstrated anddiovascular Surgery c Volume 145, Number 5 1211
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patients experiencing VAs within 1 week postoperatively.1
Bedi and colleagues1 reported an overall mortality of
33% in recipients of pulsatile LVADs experiencing postop-
erative VAs compared with 18% when no VA was present
(P<.001). Our study failed to show a mortality difference
associated with postoperative VAs but nevertheless con-
firms that a targeted treatment strategy for arrhythmia pre-
vention after LVAD is needed.
Performance of intraoperative cryoablation through the
LVADventriculotomy has not been reported by other groups,
but intraoperative epicardial and endocardial cryoablation
during cardiac surgery is by no means a new technique.18
In 1994, Dor and colleagues19 reported that cryoablation in
combination with surgical ventricular reconstruction (SVR)
with myocardial scar resection reduced spontaneous and in-
ducible arrhythmias in patients with ischemicVAs. A total of
106 patients were found to have inducible (57) or spontane-
ous (49) ventricular tachycardia preoperatively and 67 pa-
tients underwent non–EP-guided cryoablation at the time
of SVR. Postoperatively, ventricular tachycardia was no lon-
ger inducible in 92%of patients andonly 2 patients had spon-
taneous ventricular tachycardia. When following the Dor
technique for SVR, intraoperative cryoablation is performed
byvisual inspectiononlywhen the patient has spontaneous or
inducible VA preoperatively.18,20-22 The goal of SVR is to
achieve complete coronary revascularization, reduce left
ventricular volume, and restore left ventricular shape to
relieve ischemia and reduce wall tension. When combining
these principles with myocardial scar resection and visually
directed epicardial and endocardial cryoablation, Dor and
associates19 and subsequent groups23,24 have achieved
durable arrhythmia-free survival after SVR.
LVAD placement targets a similar patient population to
SVR, and although our described technique did not incorpo-
rate scar resection, we contend that the LVAD-mediated
ventricular decompression along with directed cryoablation
of ventricular scar and surrounding tissue achieves a similar
result. Notably in the LVAD population, postoperative de-
vice support allows for more aggressive use of cryoablation
without concerns for reduction in ventricular function. With
increased experience using this technique, we have gained
comfort performing cryoablation on large sections of ven-
tricle. In fact, in those patients in whom a complete EPmap-
ping study is not feasible and electrocardiographic capture
of the VA is difficult, we have ablated almost the entire epi-
cardial and endocardial surfaces of the left ventricle with
excellent results. Therefore, although our methods differ
from the Dor technique, it should not be surprising that
the combination of ventricular decompression and effective
cryoablation was similarly effective at reducing postopera-
tive VAs when applied to the LVAD patient population.
Cryoablation during LVAD implantation is a promising
technique but optimal patient selection and preoperative1212 The Journal of Thoracic and Cardiovascular Surtargeting require further definition and refinement. In our
small series, intraoperative epicardial and endocardial cry-
oablation have significantly reduced the postoperative ar-
rhythmia burden and resulted in improved patient
outcomes. At the very least, our presented results offer
a starting place toward the goal of eliminating VAs after
LVAD placement. Going forward, we recommend intrao-
perative cryoablation in all patients with a history of recur-
rent VA. In the remainder of patients, EP-programmed
electrical stimulation may be performed and if spontaneous
or inducible ventricular tachycardia is present, cryoablation
should be considered at the time of LVAD implantation.
Limitations
Our study has several limitations. First, the study was ret-
rospective with a limited follow-up time. All patients who
had postoperative VAs did so within 30 days of surgery,
but longer follow-up is needed to analyze the durability of
cryoablation for long-term limitation of postoperative VAs.
Additionally, groups were separated by chronologic series,
and a component of the cryoablation treatment effect could
possibly be attributed to improvements in intraoperative
and postoperative care associatedwith increased experience.
We do not believe this is the case inasmuch as Pre-Index and
Post-Index patients had similar ICU and hospital lengths of
stay despite identical chronologic division to the NoCryo
and Cryo groups. Additionally, although we acknowledge
that there is no direct link between the presence of recurrent
postoperativeVA and the cohort of complications and length
of stay data analyzed, previous studies have demonstrated
both decreased LVAD flows and increased mortality in pa-
tients who have postoperative VAs. It should be expected
that LVAD recipients with recurrent postoperative VAs
will require additional ICU and hospital lengths of stay
and may have additional complications related to prolonged
convalescence, low flow states, or other factors. Neverthe-
less, correlation is not causation and we cannot determine
the exact role VAs played in the observed increases in length
of stay and complications of the NoCryo group.
A further limitation is that the very small sample size of
relatively homogeneous patients limits the generalizability
of our approach. Ablation was performed only on LVAD
recipients with recurrent preoperative VAs. Many LVAD re-
cipients have no preoperative history but do suffer from post-
operative VAs, and we are unable to determine whether these
patients stand to benefit from intraoperative ablation. Finally,
all patients underwent LVAD implantation with a single de-
vice (HeartMate II) and we are unable to determine whether
our techniquewould have equal benefit when used with other
devices.
CONCLUSIONS
VAs are common after LVAD placement and their pres-
ence contributes to morbidity and mortality after thisgery c May 2013
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Dprocedure. Postoperative VAs must be limited to realize op-
timal results after LVAD placement. We have shown that in-
traoperative epicardial and endocardial cryoablation, when
performed during LVAD implantation, reduces the inci-
dence of clinically significant postoperative VAs in a small
series of high-risk patients. Optimal application of this tech-
nique will require further refinement with focused analysis
designed to answer the questions of whom to treat and
where to ablate. Widespread adoption of this technique
should be feasible both in the United States and worldwide
inasmuch as it is safe, easy, and adds minimal time and cost
to the standard LVAD implantation procedure. Our promis-
ing initial experience with intraoperative cryoablation ar-
gues for further application of this novel technique
combined with systematic prospective analysis to refine op-
timal patient selection and application methods.
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